Concord Biotech Limited announced its unaudited financial results for the third quarter ended December 31, 2025, following a Board meeting on February 11, 2026. The Board approved both standalone and consolidated results, which received an unmodified opinion upon limited review. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary, Compliance Officer, and Nodal Officer, effective the same day.
Board Approves Q3 and Nine-Month Financial Results
The Board of Directors of Concord Biotech Limited convened on Wednesday, February 11, 2026, to review and approve the financial performance for the third quarter and the nine months ending December 31, 2025. The results, covering both Standalone and Consolidated statements, were subject to a Limited Review by the Statutory Auditors, M/s. BSR & Co. LLP, who issued an Unmodified Opinion.
Key Standalone Financial Highlights (Q3 Ended Dec 31, 2025)
The standalone results show significant year-over-year comparison figures for the quarter:
- Total Income: ₹28,774.22 Lakhs, compared to ₹25,894.96 Lakhs in the corresponding quarter last year.
- Profit Before Tax (PBT): ₹8,685.28 Lakhs (before exceptional items), compared to ₹9,932.00 Lakhs in Q3 FY2024-25. (Note: PBT after exceptional items was ₹8,615.59 Lakhs).
- Profit After Tax (PAT) attributable to owners: ₹6,447.66 Lakhs.
- Total Comprehensive Income attributable to owners: ₹8,745.63 Lakhs.
Key Consolidated Financial Highlights (Q3 Ended Dec 31, 2025)
Consolidated figures reflect the inclusion of subsidiaries and the joint venture:
- Total Consolidated Income: ₹27,776.60 Lakhs.
- Profit Before Tax (PBT) (after joint venture share): ₹8,615.59 Lakhs.
- Consolidated Profit After Tax (PAT) attributable to owners: ₹6,364.15 Lakhs.
Exceptional Item Disclosure
In the standalone results, the company recognized an exceptional item of ₹327.54 Lakhs related to the incremental liability arising from the Government of India’s notification of four new Labour Codes. This was assessed based on management’s valuation and disclosed separately.
Appointment of Key Managerial Personnel (KMP)
The Board, upon the recommendation of the Nomination and Remuneration Committee, approved a key management change:
- New KMP: Mr. Paritosh Trivedi (Membership No. A63623) has been appointed as the Company Secretary, Compliance Officer, and Nodal Officer.
- Effective Date: February 11, 2026.
- Profile: Mr. Trivedi is an Associate Member of the Institute of Company Secretaries of India, possessing approximately 5 years of experience in corporate compliance and governance across various sectors.
Consolidated Entities Overview
The consolidation includes the results of:
- Concord Lifegen Limited (Wholly owned subsidiary, effective July 21, 2025).
- Stellon Biotech Inc. (Subsidiary, effective July 1, 2025).
- Concord Biotech Japan K.K. (Joint Venture).
Notably, the interim financial information of two subsidiaries was not reviewed, but management deemed their impact not material to the Group’s overall results.
Source: BSE
